Combined therapeutic effect of a monoclonal anti-idiotype tumor vaccine against NeuGc-containing gangliosides with chemotherapy in a breast carcinoma model

Breast Cancer Research and Treatment

Volumn 120, Issue 2, 2010, Pages 379-389

  Fuentes, D ^a   Avellanet, J ^b   Garcia, A ^a   Iglesias, N ^c   Gabri, M R ^d   Alonso, D F ^d   Vazquez, A M ^b   Perez, R ^b   Montero, E ^b  

^a National Center   (Cuba)

^b CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^c HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

^d UNIVERSIDAD NACIONAL DE QUILMES   (Argentina)

Author keywords

Angiogenesis; Anti idiotype monoclonal antibody; Breast cancer; Cancer vaccine; Chemotherapy; Combinatorial therapy; Myeloid cells gr1+ cd11b+ apoptosis; Neugc containing ganglioside

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CANCER VACCINE; CD11B ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GANGLIOSIDE; RACOTUMOMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CANCER VACCINES; CYCLOPHOSPHAMIDE; FEMALE; GANGLIOSIDES; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77950690146     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0399-9     Document Type: Article

References (52)

1. 1. Montero E, Amador JF, Perez R, Lage A (2000) Tumor-specific immunotherapy based on dominant models of natural tolerance. Med Hypotheses 54:531-536. doi:10.1054/mehy.1999.0892 (Pubitemid 30311541)
2. Bhattacharya-Chatterjee M, Chatterjee SK, Foon KA (2001) The anti-idiotype vaccines for immunotherapy. Curr Opin Mol Ther 3:63-69
3. 3. Mohanty K, Saha A, Pal S, Mallick P, Chatterjee SK, Foon KA, Bhattacharya-Chatterjee M (2007) Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 104:1-11, doi:10.1007/s10549-006-9391-9 (Pubitemid 46976632)
4. 4. Vazquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, Perez R (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti.-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17:527-534 (Pubitemid 29024638)
5. Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R (2000) Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 7:751-756
6. Diaz Y, Gonzalez A, Lopez A, Perez R, Vazquez AM, Montero E (2008) Anti-ganglioside anti-idiotypic monoclonal antibodybased cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother
7. + cells. Cancer Res 65:7493-750.1. doi:10.1158/0008-5472.CAN- 04-3808
8. Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA et al (2003) Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin Breast Cancer 3(Suppl 4):S152-S157. doi:10.3816/CBC.2003.s.005
9. Sinkovics JG, Horvath JC (2006) Evidence accumulating in support of cancer vaccines combined with chemotherapy: a pragmatic review of past and present efforts. Int J Oncol. 29: 765-777
10. 10. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 1.05:1045-1047. doi:10.1172/JCI9872 (Pubitemid 30217688)
11. 11. Fisher B, Brown AM, Dimitrov NV, Poisson R, Redmond C, Margolese RG, Bowman D, Wolmark N, Wickerham DL, Kardinal CG et al (1990) Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496 (Pubitemid 20301179)
12. 12. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878-1886 (Pubitemid 30207647)
13. 13. Loeffler M, Kruger JA, Reisfeld RA (2005) Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res 65:5027-5030, doi:10.1158/0008-5472.CAN-05-0646 (Pubitemid 40827309)
14. 14. Alonso DF, Farias EF, Urtreger A, Ladeda V, Vidal MC, Bal De Kier Joffe E (1996) Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. J Surg Oncol 62:288-297. doi:10.1002/(SICI)1096-9098(199608)62:4<288::AID-JSO14> 3.0.CO;2-1 (Pubitemid 26262354)
15. 15. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE (1998) Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 50: 83-93. doi:10.1023/A:1006058409974 (Pubitemid 28438864)
16. 16. Trump BF, Berezesky IK, Chang SH, Phelps PC (1997) The pathways of cell death: oncosis, apoptosis, and necrosis. Toxicol Pathol 25:82-88 (Pubitemid 27100564)
17. Coro RM, Borrajero I (1996) DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev Latinoam Patol 34:9-10
18. Gabri MR, Menna PL, Scursoni AM, Gomez DE, Alonso DF (1999) Role of tumor-derived granulocyte-macrophage colonystimulating factor in mice bearing a highly invasive and metastatic mammary carcinoma. Pathobiology 67:180-185. doi:10.1159/000028070
19. Bronte V, Apolloni E, Cabrelle A, Ronca R, Serafini P, Zamboni P, Restiro NP, Zanovello P (2000) Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells. Blood 96:3838-3846
20. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70. doi:10.101.6/S0092-8674(00)81683-9
21. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS (2006) Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 1.2:904-916. doi:10.1158/1078-0432.CCR-05-1109
22. 22. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O, Perez R, Ando S (1996) Gangliosides expressed in human breast cancer. Cancer Res 56:5165-5171 (Pubitemid 26383031)
23. 23. Bada A, Casaco Parada A, Arteaga M., Martinez J, Leon A, Santana E, Hernandez O, Orphee R, Gonzalez A, Mesa C et al (2002) Toxicity of a GM3 cancer vaccine in Macaca fascicularis monkey: a 12-month study. Hum Exp Toxicol 21:263-267. doi:10.1191/0960327102ht248oa (Pubitemid 34785027)
24. Oliva JP, Valdes Z, Casaco A, Pimentel G, Gonzalez J, Alvarez I, Osorio M, Velazco M, Figueroa M, Ortiz R et al (2006) Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99 m)Tc. Breast Cancer Res Treat 96:115-121. doi:10.1007/s10549-005-9064-0
25. Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Perez R (2008) Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 7:2033-2041. doi:10.1158/1535-7163.MCT-08-0222
26. Lake RA, Robinson BW (2005) Immunotherapy and chemotherapy-a practical partnership. Nat Rev Cancer 5:397-405. doi:10.1038/nrc1613
27. 27. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Menard C, Ghiringhelli F, Terme M, Carpentier AF, Darrasse-Jeze G et al (2006) Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 176:2722-2729 (Pubitemid 43306930)
28. 28. Carter MR, Hornick JL, Lester S, Fletcher CD (2006) Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol 30:300-309 (Pubitemid 43740161)
29. Nowak AK, Lake RA, Robinson BW (2006) Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58:975-990. doi:10.1016/j.addr.2006.04.002
30. 30. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15-R24. doi:10.1172/JCI8829 (Pubitemid 30217701)
31. 31. Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Perez R, Vazquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107:80-89. doi:10.1016/S1521-6616(03)00036-6 (Pubitemid 36579371)
32. 32. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vazquez AM, Fainboim L (2006) Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29:215-223. doi:10.1097/01.cji.0000188502.11348.34 (Pubitemid 43756097)
33. 33. Zhou H, Sequeira M, Goad ME, Erickson J, Wong A, Clark E, Dunussi-Joannopoulos K, Li RC, Friedrich S, Hayes LL et al (2001) Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with adriamycin and Cytoxan chemotherapy. Clin Immunol 101:303-314. doi:10.1006/clim.2001.5123 (Pubitemid 33145014)
34. 34. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5, 6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61:1948-1956 (Pubitemid 32692012)
35. 35. Machieis JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, Okoye FI, Jaffee EM (2001) Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factorsecreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res 61:3689-3697 (Pubitemid 32694981)
36. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB (2004) Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 6:R275-R283. doi:10.1186/bcr787
37. Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T (2006) Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int J Mol Med 17:1045-1052
38. 38. Rice J, Dunn S, Piper K, Buchan SL, Moss PA, Stevenson FK (2006) DNA fusion vaccines induce epitope-specific cytotoxic CD8(+) T cells against human leukemia-associated minor histocompatibility antigens. Cancer Res 66:5436-5442. doi:10.1158/0008-5472.CAN-05-3130 (Pubitemid 43844971)
39. 39. Emens LA, Jaffee EM (2005) Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res 65:8059-8064. doi:10.1158/0008-5472.CAN- 05-1797 (Pubitemid 41330564)
40. 40. Montero E, Alonso L, Perez R, Lage A (2007) Interleukin-2 mastering regulation in cancer and autoimmunity. Ann N Y Acad Sci 1107:239-250. doi:10.1196/annals. 1381.026 (Pubitemid 47528801)
41. Shojaei F, Ferrara N (2008) Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells. Cancer Res 68:5501-5504. doi:10.1158/0008-5472.CAN-08-0925
42. 42. Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H (2008) Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res 68:1563-1571. doi:10.11.58/0008-5472. CAN-07-5324 (Pubitemid 351346866)
43. Ercolini AM, Ladle BH, Manning EA, .Pfannenstiel LW, Armstrong TD, Machieis JP, Bieler JG, Emens LA, Reilly RT, Jaffee EM (2005) Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 201:1591-1602. doi:10.1084/jem.20042167
44. 44. Kroemer G, Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-482. doi:1.0.10.16/j.ccr.2008.05.005 (Pubitemid 351766797)
45. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G (2008) The anticancer immune response: indispensable for therapeutic success? J Clin Invest 118:1991-2001. doi:10.1172/JCI35180
46. 46. Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumorinduced immune dysfunctions caused by myeloid suppressor cells. J Immunother 24:431-446 (Pubitemid 33104863)
47. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11:6713-6721. doi:10.1158/1078-0432.CCR-05-0883
48. 48. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V, Borrello I (2006) Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 203:2691-2702. doi:10.1084/jem.20061104 (Pubitemid 44833345)
49. Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704-2715. doi:10.1056/NEJMra072739
50. Finn OJ (2008) Tumor immunology top 10 list. Immunol Rev 222:5-8. doi:10.1111/j.1600-065X.2008.00623.x
51. Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, Lage A, Montero E (2008) Priming and boosting determinants on the antibody response to an epidermal growth factor-based cancer vaccine. Vaccine 26:4647-4654. doi:10.1016/j.vaccine.2008.07.003
52. Montero E, Valdes M, Avellanet J, Lopez A, Perez R, Lage A (2009) Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 27:2230-2239. doi:10.1016/j.vaccine.2009.02.018